We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
Read MoreHide Full Article
Key Takeaways
GSK's Arexvy filing seeks FDA approval for use in high-risk adults under age 50.
Late-stage trial data showed Arexvy's safety matched results from previous vaccine studies.
Arexvy's sales dropped 51% in 2024 amid tighter U.S. guidelines and rising vaccine competition.
GSK plc (GSK - Free Report) announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision is expected in the first half of 2026.
Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59. If approved for the younger population, the GSK vaccine would become the third FDA-approved RSV vaccine in this age group, joining Pfizer’s (PFE - Free Report) Abrysvo and Moderna’s (MRNA - Free Report) mResvia.
The filing is supported by data from a late-stage study, which showed that Arexvy’s safety and reactogenicity profile was consistent with those seen in previously conducted studies on the vaccine.
Year to date, shares of GSK have gained 13% against the industry’s 1% decline.
Image Source: Zacks Investment Research
GSK’s RSV Vaccine Sales Under Pressure
Arexvy has been one of GSK’s top-selling products since its initial approval in 2023. However, the vaccine’s sales were significantly impacted last year, declining 51% year over year to £590 million (around $755 million) in full-year 2024. This drop was largely due to narrower vaccination recommendations issued by the U.S. Advisory Committee on Immunization Practices (“ACIP”).
In June 2024, the ACIP recommended Arexvy for adults aged 75 and older. However, for those aged 60-74, the guidance limited vaccination to individuals at increased risk of severe RSV disease — a decision that reduced the eligible population and weighed on demand.
Meanwhile, GSK’s competitive position has weakened. Although Arexvy was the first RSV vaccine approved in the United States, both Pfizer and Moderna have since gained regulatory approval for broader adult use, covering high-risk individuals aged 18–74, in addition to the 75 and older age group. Pfizer’s Abrysvo also holds a unique position as the only RSV vaccine approved for use in infants via maternal immunization during pregnancy.
Competitive Landscape for RSV Vaccines
Despite the setbacks, the outlook for the upcoming RSV season appears more favorable. Recently, the CDC updated its guidelines to recommend vaccination for high-risk adults aged 50-59, a group for which Arexvy is already approved.
While Pfizer and Moderna hold FDA approvals for high-risk adults under 50, the absence of CDC guidance for this group puts all three vaccine-makers — GSK, Pfizer and Moderna — on relatively equal footing. With regulatory decisions pending and public health policy on RSV vaccines still evolving, the next wave of updates could play a pivotal role in determining which vaccine-maker secures an early advantage in the under-50 segment.
Image: Bigstock
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
Key Takeaways
GSK plc (GSK - Free Report) announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision is expected in the first half of 2026.
Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59. If approved for the younger population, the GSK vaccine would become the third FDA-approved RSV vaccine in this age group, joining Pfizer’s (PFE - Free Report) Abrysvo and Moderna’s (MRNA - Free Report) mResvia.
The filing is supported by data from a late-stage study, which showed that Arexvy’s safety and reactogenicity profile was consistent with those seen in previously conducted studies on the vaccine.
A similar regulatory filing was accepted by the EMA last month, with approval also expected early next year.
GSK Stock’s Performance
Year to date, shares of GSK have gained 13% against the industry’s 1% decline.
Image Source: Zacks Investment Research
GSK’s RSV Vaccine Sales Under Pressure
Arexvy has been one of GSK’s top-selling products since its initial approval in 2023. However, the vaccine’s sales were significantly impacted last year, declining 51% year over year to £590 million (around $755 million) in full-year 2024. This drop was largely due to narrower vaccination recommendations issued by the U.S. Advisory Committee on Immunization Practices (“ACIP”).
In June 2024, the ACIP recommended Arexvy for adults aged 75 and older. However, for those aged 60-74, the guidance limited vaccination to individuals at increased risk of severe RSV disease — a decision that reduced the eligible population and weighed on demand.
Meanwhile, GSK’s competitive position has weakened. Although Arexvy was the first RSV vaccine approved in the United States, both Pfizer and Moderna have since gained regulatory approval for broader adult use, covering high-risk individuals aged 18–74, in addition to the 75 and older age group. Pfizer’s Abrysvo also holds a unique position as the only RSV vaccine approved for use in infants via maternal immunization during pregnancy.
Competitive Landscape for RSV Vaccines
Despite the setbacks, the outlook for the upcoming RSV season appears more favorable. Recently, the CDC updated its guidelines to recommend vaccination for high-risk adults aged 50-59, a group for which Arexvy is already approved.
While Pfizer and Moderna hold FDA approvals for high-risk adults under 50, the absence of CDC guidance for this group puts all three vaccine-makers — GSK, Pfizer and Moderna — on relatively equal footing. With regulatory decisions pending and public health policy on RSV vaccines still evolving, the next wave of updates could play a pivotal role in determining which vaccine-maker secures an early advantage in the under-50 segment.
GSK PLC Sponsored ADR Price
GSK PLC Sponsored ADR price | GSK PLC Sponsored ADR Quote
GSK’s Zacks Rank
GSK currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.